Welcome to our dedicated page for Merus SEC filings (Ticker: MRUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Merus N.V. (MRUS) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a Nasdaq-listed issuer. These filings document Merus’ activities as an oncology company developing Multiclonics® bispecific and trispecific antibody therapeutics, including programs such as petosemtamab and BIZENGRI®.
Key filings include Form 8-K current reports, which Merus uses to describe material events. An 8-K dated September 29, 2025 outlines the transaction agreement under which Genmab A/S, through a wholly owned subsidiary, agreed to commence a tender offer to acquire all issued and outstanding Merus common shares for cash, followed by back-end transactions intended to make Merus an indirect wholly owned subsidiary. Another 8-K dated December 12, 2025 reports the completion of the initial tender offer period, acceptance of shares representing approximately 94.2% of the issued and outstanding share capital, the resulting change of control, and the commencement of a subsequent offering period.
These and related filings also describe expected post-closing steps, including back-end reorganization transactions, planned delisting of Merus common shares from the Nasdaq Stock Market and subsequent deregistration under the Securities Exchange Act of 1934. Together, they provide a regulatory record of the acquisition process and the modification of rights of Merus security holders.
In addition to transaction-related reports, Merus files periodic reports such as Form 10-Q and Form 10-K, which include financial statements, discussion of collaboration revenue, research and development expenses, and risk factors related to its oncology pipeline and partnerships. Investors can also review disclosures on equity awards, inducement grants under Nasdaq Listing Rule 5635(c)(4), and other governance matters.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand tender offer terms, changes in control, delisting plans, clinical program updates and other material information contained in Merus’ SEC submissions.
Peter B. Silverman, COO & General Counsel of Merus N.V. (MRUS), executed a planned transaction under Rule 10b5-1 on June 20, 2025. The transaction involved:
- Exercise of 34,000 stock options at $18.61 per share
- Immediate sale of all 34,000 shares at a weighted average price of $52.76 (range: $52.44-$53.06)
- Retained 23,500 unexercised options from original February 14, 2020 grant
This transaction was conducted according to a pre-established Rule 10b5-1 trading plan adopted on March 20, 2025. The exercised options were fully vested, with an original expiration date of February 14, 2030. The sale represents a significant realization of gains, with approximately $1.16 million in gross proceeds before accounting for the exercise cost of $632,740.